IPO Guru

IPO Listed — 27 Feb 2026

Listing Price: ₹83.00

vs Issue Price ₹79 +₹4 (+5.06%)

Gaudium IVF IPO GMP History | Listing Price ₹83.00 & Kostak Rate

IPO
Final GMP
₹ -5
-6%
Final Kostak
Retail ₹ 0
SHNI ₹ 0
BHNI ₹ 0
Final Sub. to Sauda
Retail ₹ 0
SHNI ₹ 0
BHNI ₹ 0

Gaudium IVF IPO has been listed on February 27, 2026 at a listing price of ₹83.00, against the issue price of ₹79 — a gain of ₹4 (+5.06%). The GMP peaked at ₹15 on 17 February 2026 and reached a low of ₹-5 on 27 February 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.

Gaudium IVF IPO raised ₹165 Cr. through its IPO at a price band of ₹75 to ₹79 per share, with a lot size of 189 shares. The IPO was open for subscription from 20 Feb 2026 to 24 Feb 2026.

GMP Trend Chart

Day-wise GMP Trend

Date GMP ↑↓ % Kostak Sub. Sauda
27 Feb 2026 ₹ -5 -6% ₹ 0 ₹ 0
26 Feb 2026 ₹ -5 -6% ₹ 0 ₹ 0
25 Feb 2026 ₹ -2 -3% ₹ 0 ₹ 0
24 Feb 2026 ₹ 4 5% ₹ 0 ₹ 700
23 Feb 2026 ₹ 5 6% ₹ 0 ₹ 700
22 Feb 2026 ₹ 8 10% ₹ 0 ₹ 1200
21 Feb 2026 ₹ 8 10% ₹ 0 ₹ 1200
20 Feb 2026 ₹ 8 10% ₹ 0 ₹ 1400
19 Feb 2026 ₹ 9 11% ₹ 0 ₹ 1400
18 Feb 2026 ₹ 12 15% ₹ 0 ₹ 0
17 Feb 2026 ₹ 15 19% ₹ 0 ₹ 0
16 Feb 2026 ₹ 0 -- ₹ 0 ₹ 0
14 Feb 2026 ₹ 0 -- ₹ 0 ₹ 0

Gaudium IVF IPO Dates

Event Date
Open Date 20 Feb, 2026
Close Date 24 Feb, 2026
Allotment Date 25 Feb, 2026
Refund Date 26 Feb, 2026
Credit to Demat 26 Feb, 2026
Listing Date 27 Feb, 2026

Gaudium IVF IPO Actual Listing Price

Basis Value
Issue Price ₹79
GMP-Based Estimate (Pre-Listing) ₹74 (-6.3%)
Actual Listing Price ₹83.00 (+5.06%)
Listing Gain / Loss +₹4 per share
Listing Date 27 Feb, 2026

Is Gaudium IVF IPO GMP Reliable?

Grey market premium for Gaudium IVF IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:

  • Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
  • Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
  • Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
  • Cross-check before acting: Review the Gaudium IVF IPO full review for a fundamentals-based assessment before making any grey market trades.

Gaudium IVF IPO IPO Kostak Rate Explained

The Kostak rate for Gaudium IVF IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.

The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.

Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.

About Gaudium IVF IPO

Gaudium IVF is a rapidly growing fertility care provider in India, focused on offering advanced reproductive treatments with a patient-centric approach. The company was founded by Dr. Manika Khanna, a well-known fertility expert, with the aim of making high-quality infertility treatments accessible and affordable. Since its inception, Gaudium IVF has expanded its footprint across multiple cities, building a strong reputation for ethical practices, transparent processes, and high success rates. The organisation combines medical expertise with modern infrastructure to address a wide range of fertility challenges faced by couples.

The company offers a comprehensive suite of services including IVF (in-vitro fertilisation), IUI (intrauterine insemination), ICSI, egg freezing, fertility preservation, and advanced diagnostic solutions. Its business model is primarily clinic-based, generating revenue through treatment cycles, consultations, and specialised procedures. Gaudium IVF focuses on personalised treatment plans, leveraging technology and experienced medical professionals to improve outcomes. By maintaining quality standards and expanding through new centres and partnerships, the company aims to strengthen its presence in India’s growing fertility services market while ensuring consistent patient care and long-term trust.

Frequently Asked Questions about Gaudium IVF IPO

What is the GMP of Gaudium IVF IPO?

The current Grey Market Premium (GMP) of Gaudium IVF IPO is ₹ -5.

What is the Kostak Price of Gaudium IVF IPO?

Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Gaudium IVF IPO is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.

What is the Subject to Sauda Price of Gaudium IVF IPO?

Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.

What was the actual listing price of Gaudium IVF IPO?

Gaudium IVF IPO listed on February 27, 2026 at ₹83.00, against the issue price of ₹79 — a gain of +5.06%.

How did the GMP of Gaudium IVF IPO trend before listing?

The GMP of Gaudium IVF IPO was stable in its final days before listing. The GMP peaked at ₹15 on 17 February 2026. View the day-wise table above for the complete GMP history.

Explore Gaudium IVF IPO Further

For a complete picture before making your investment decision, explore these resources:

Discussion 1

💡
Commenting as
Markdown supported: **bold**, _italics_
Ajay Guest

This IPO is looking very nice, all three things Review, GMP and Subscription helped me to make my decision of Applying this IPO.

Commenting as
Markdown supported: **bold**, _italics_
Advertisement